BIO Is Helping Companies Boost Minority Participation In Clinical Trials
BIO head Michelle McMurry-Heath discusses group’s efforts to increase enrollment of people of color in COVID-19 clinical trials and why New York’s task force to give second review to COVID-19 vaccines is “dangerous for patients.”
You may also be interested in...
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.